The effect of a new anti-inflammatory agent (5-cyclohexylindan-1-carboxylic acid (BL-2365)) on platelet aggregation.
D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D002264:Carboxylic Acids / Q000008:administration & dosage / Q000494:pharmacology; D003094:Collagen / Q000494:pharmacology; D003510:Cyclohexanes / Q000008:administration & dosage / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000633:toxicity; D006487:Hemostasis; D007192:Indenes / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D010653:Phenylbutazone / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011817:Rabbits; D051381:Rats
D000893:Anti-Inflammatory Agents; D002264:Carboxylic Acids; D003510:Cyclohexanes; D004731:Endotoxins; D007192:Indenes; D003094:Collagen; D010653:Phenylbutazone; D001241:Aspirin